Considerations for drug dosing post coronary artery bypass graft surgery

Annals of Pharmacotherapy

Volumn 42, Issue 3, 2008, Pages 421-424

  Dager, William E ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Argatroban; Coronary bypass graft surgery; Direct thrombin inhibitors; Heart failure; Heparin induced thrombocytopenia

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; ARGATROBAN; BLOOD CLOTTING FACTOR 7; HEPARIN; THROMBIN INHIBITOR;

BLEEDING; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REGIMEN; DRUG ELIMINATION; HEART DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFUSION RATE; KIDNEY DISEASE; LIVER DISEASE; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK; THROMBOSIS;

ANTICOAGULANTS; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPECOLIC ACIDS;

EID: 41149154896     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L009     Document Type: Review

References (12)

1. Hoffman WD, Czyz D, Hursting MJ. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008;42:309-16.
2. Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: a review of treatment options and special considerations. Pharmacotherapy 2007;27:564-87.
3. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4. DOI 10.1345/aph.1C187
4. Kuitunen A, Suojaranta-Ylinen R, Raivio P, Kukkonen S, Lassila R. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. J Cardiothorac Vasc Anesth 2007;21:18-22.
5. Puoplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005;128:837-41.
6. Greinacher A, Eicher P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
7. White MC, Pryn SJ, Monk CR. Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery. Anaesth Intensive Care 2006;34:664-7.
8. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
9. Kress DC, Aronson S, McDonald ML, et al. Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. Ann Thoracic Surg 2007;83:1737-43.
10. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55.
11. Chong BH, Chong JH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2004;2:547-59.
12. Janatpour KA, Gosselin RC, Dager WE, Lee A, Owings JT, Wun T. Usefulness of optical density values from heparin-platelet factor 4 antibody testing and probability scoring models to diagnose heparin-induced thrombocytopenia. Am J Clin Pathol 2007;127:429-33.